Peptide Profile
Teduglutide
Gattex · Revestive · GLP-2 analogue
Teduglutide (Gattex in the United States, Revestive in the European Union) is a GLP-2 analogue and FDA-approved prescription medication indicated for short bowel syndrome (SBS) with intestinal failure in adults and pediatric…
- Half-life
- ~2 hours
- Routes
- subcutaneous
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
What Teduglutide is
About Teduglutide
GLP-2 receptor agonist; stimulates intestinal epithelial proliferation and reduces apoptosis; increases intestinal blood flow and inhibits gastric motility
Teduglutide (Gattex in the United States, Revestive in the European Union) is a GLP-2 analogue and FDA-approved prescription medication indicated for short bowel syndrome (SBS) with intestinal failure in adults and pediatric patients, designed to reduce dependence on parenteral nutrition and intravenous fluids by promoting intestinal mucosal growth and enhancing residual bowel absorptive capacity. By activating GLP-2 receptors on intestinal subepithelial myofibroblasts and enteric neurons, teduglutide stimulates paracrine release of insulin-like growth factor 1 (IGF-1) and keratinocyte growth factor (KGF), driving enterocyte crypt cell proliferation, increasing villus height, and expanding mucosal absorptive surface area to improve nutrient and fluid absorption from functionally compromised residual bowel. A systematic review and meta-analysis of Phase 3 registrational trial data published in the Journal of Parenteral and Enteral Nutrition documented significant reductions in parenteral nutrition volume requirements, and long-term follow-up data published in Clinical and Translational Gastroenterology confirmed durable reductions in parenteral support needs over extended treatment periods. Teduglutide is an FDA-approved prescription medication; it is indicated for adults and pediatric patients (≥1 year) with SBS dependent on parenteral support, and use outside this indication or without physician supervision is not supported by established safety and efficacy data.
Teduglutide Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Teduglutide half-life calculator
Compound & timing
Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.
What the evidence says about Teduglutide
Research Evidence
based on 8 studies · most recent 2026
Regulatory Status
- Availability Status
- Prescription
- FDA Status
- FDA Approved
- Effective Date
- December 21, 2012
- Source
- View FDA source →
FDA-approved GLP-2 analog. Brand: Gattex (NDA 203441, Dec 2012). Indicated for short bowel syndrome in adults and paediatric patients. Daily subcutaneous injection. Prescription only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
8 sources cited · 4 moderate · 4 weak
3 Cohorts · 1 Case series · 3 Reviews · 1 Animal
From childhood to adulthood in chronic intestinal failure: A nationwide study.
Clin Nutr · 2026
# Summary This nationwide study demonstrated that teduglutide was the only therapeutic factor associated with reduced dependence on home parenteral nutrition in adults who had childhood-onset chronic intestinal failure. Research found that while survival rates remained high (91%) in this patient population, persistent parenteral nutrition dependence (95%) was common, suggesting that GLP-2 analogues like teduglutide may offer a meaningful therapeutic avenue for improving long-term outcomes.
PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.
JPGN Rep · 2026
# Summary Research found that teduglutide enabled a child with a novel PERCC1 gene mutation causing severe congenital enteropathy to achieve independence from parenteral nutrition after two years of dependency. This study demonstrated that teduglutide may represent a therapeutic option for reducing nutritional support requirements in certain genetic forms of congenital diarrhea and enteropathy.
Growth trajectories of children with short bowel syndrome during the first year of teduglutide treatment.
Clin Nutr · 2026
Show 5 more sources ↓
Real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure.
Clin Nutr ESPEN · 2026
Research found that in real-world clinical practice, patients with short bowel syndrome-associated intestinal failure experienced reductions in parenteral nutrition and intravenous fluid dependence whether or not they received teduglutide treatment, with similar overall reductions in PN/IV frequency and volume observed in both groups over approximately 19 months of follow-up. This study demonstrated that while teduglutide-treated patients showed slightly higher reductions in energy received from PN/IV support, the differences between treated and untreated cohorts were modest, suggesting variable treatment responses in clinical practice settings.
A Long-Acting Glucagon-like Peptide 2 Protracted by Coomassie Brilliant Blue to Enhance Intestinal Growth in Mice.
Bioconjug Chem · 2026
# Summary Research found that a modified version of teduglutide created by conjugating Coomassie brilliant blue demonstrated significantly extended circulation time in the body while maintaining therapeutic potency and producing enhanced intestinal growth in mice. This study demonstrated that the modified compound achieved greater intestinal tissue development compared to standard teduglutide, suggesting potential for reducing injection frequency in treatment approaches.
Glucagon-like peptide agonists and use in short bowel syndrome - what about the side effects?
Curr Opin Gastroenterol · 2026
# Summary Research found that GLP-2 agonists, particularly teduglutide, demonstrate improvements in intestinal absorption and reduce the need for parenteral support in short bowel syndrome patients while maintaining favorable safety profiles. This study identified emerging longer-acting agents as promising alternatives with less frequent dosing requirements and noted that GLP-1 agonists may offer complementary benefits for future treatment strategies.
Beyond intestinal failure: Expanding therapeutic frontiers of glucagon-like peptide-2 in gastrointestinal disease.
World J Gastrointest Pharmacol Ther · 2026
Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review
Journal of Parenteral and Enteral Nutrition · 2015
This systematic review of phase 3 randomized controlled trials and extension studies found that teduglutide (a GLP-2 analog) consistently reduced parenteral nutrition requirements compared with placebo in adults with intestinal failure, with an adverse event profile comparable to placebo, supporting its role in promoting intestinal adaptation and reducing long-term parenteral dependence.
Teduglutide Side Effects & Safety Considerations
Research-use compound with limited human data. Evidence strength varies — see the Evidence section.
Reported (unverified — pending clinical review)
No established clinical contraindications
Common monitoring markers in research protocols
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSTeduglutide
Frequently Asked Questions — Teduglutide
Teduglutide (Gattex in the United States, Revestive in the European Union) is a GLP-2 analogue and FDA-approved prescription medication indicated for short bowel syndrome (SBS) with intestinal failure in adults and pediatric patients, designed to reduce dependence on parenteral nutrition and intravenous fluids by promoting intestinal mucosal growth and enhancing residual bowel absorptive capacity. By activating GLP-2 receptors on intestinal subepithelial myofibroblasts and enteric neurons, teduglutide stimulates paracrine release of insulin-like growth factor 1 (IGF-1) and keratinocyte growth factor (KGF), driving enterocyte crypt cell proliferation, increasing villus height, and expanding mucosal absorptive surface area to improve nutrient and fluid absorption from functionally compromised residual bowel.
intestinal growth, gut repair, absorptive surface restoration, short bowel syndrome treatment.
Research on Teduglutide primarily documents effects related to intestinal growth and gut repair and absorptive surface restoration and short bowel syndrome treatment. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Teduglutide include GI malignancy or history, colorectal polyps (monitor). This is educational information only — consult a qualified healthcare professional before use.
For Teduglutide, its FDA status is FDA-approved, and it is available by prescription. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
# Summary This nationwide study demonstrated that teduglutide was the only therapeutic factor associated with reduced dependence on home parenteral nutrition in adults who had childhood-onset chronic intestinal failure. Research found that while survival rates remained high (91%) in this patient population, persistent parenteral nutrition dependence (95%) was common, suggesting that GLP-2 analogues like teduglutide may offer a meaningful therapeutic avenue for improving long-term outcomes.
How to get Teduglutide
Where to buy Teduglutide
Coverage expanding
No providers currently list Teduglutide. Get notified when one does, or explore providers carrying similar peptides in the Recovery category.
Questions to ask your provider
Stay updated on Teduglutide providers
New providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.